Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness
NCT05623384 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2022-11-21
Summary
Sudden deafness is a sudden, unexplained sensorineural hearing loss of ≥20 dBHL in at least two adjacent frequencies within 72 h. It may be accompanied by tinnitus, a sense of ear congestion, vertigo and other Symptoms.Stellate ganglion block increases the blood flow and blood velocity in the inner ear, keeping the body's vegetative, endocrine and immune functions normal.The branches of the facial and linguopharyngeal nerves are connected to the inner ear, and local injection can nourish the nerves and improve local circulation.
Conditions
- Sudden Deafness
Interventions
- PROCEDURE
-
Stellate ganglion block
A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.(lidocaine 80mg;Physiological saline 1ml)
- PROCEDURE
-
Facial and glossopharyngeal nerve blocks
The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. (mecobalamin injection 1mg;lidocaine 20mg; dexamethasone 10mg ;Physiological saline 2ml)
- DRUG
-
Mecobalamin Tablets
oral Mecobalamin Tablets tid-8
Sponsors & Collaborators
-
Zhuan Zhang
lead OTHER
Principal Investigators
-
zhuan zhang, professor · The Affiliated Hospital of Yangzhou University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-14
- Primary Completion
- 2023-09-30
- Completion
- 2023-09-30
Countries
- China
Study Locations
More Related Trials
-
Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss
NCT07235488 ·Status: RECRUITING ·Phase: NA
-
Intratympanic Steroids for Sudden Hearing Loss
NCT04129697 ·Status: UNKNOWN ·Phase: NA
-
FX-322 in Adults With Acquired Sensorineural Hearing Loss
NCT05086276 ·Status: COMPLETED ·Phase: PHASE2
-
FX-322 in Sensorineural Hearing Loss
NCT03616223 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Predictive Factors for Recovery in Idiopathic Sensory Neural Hearing Loss
NCT05112354 ·Status: COMPLETED ·Phase: PHASE2
-
Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids
NCT03974867 ·Status: UNKNOWN ·Phase: NA
-
FX-322 in Adults With Severe Sensorineural Hearing Loss
NCT04629664 ·Status: COMPLETED ·Phase: PHASE1
-
FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT04120116 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection
NCT04794842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
NCT04601909 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT05786378 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Establishment of a Trans-round Window Inner Ear Continuous Drug Delivery System for the Treatment of Severe-to-profound Sudden Sensorineural Hearing Loss
NCT05455398 ·Status: UNKNOWN ·Phase: NA
-
Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo
NCT07283562 ·Status: COMPLETED ·Phase: NA
-
Small Sample,Unicentric,Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
NCT05849519 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
NCT04766853 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss
NCT05664100 ·Status: TERMINATED ·Phase: PHASE1
-
Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss
NCT06878599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss
NCT06437054 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Prevention of Noise-induced Hearing Loss
NCT02049073 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
NCT03255473 ·Status: WITHDRAWN ·Phase: PHASE2
-
Sudden Deafness Treatment Trial
NCT00097448 ·Status: COMPLETED ·Phase: PHASE3
-
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
NCT05355610 ·Status: UNKNOWN ·Phase: NA
-
Blood Markers in Adult Patients With Sudden Sensorineural Hearing Loss (SSNHL)
NCT03919474 ·Status: COMPLETED
-
Effects of Endolymphatic Sac Drainage With Steroids for Meniere's Disease
NCT00500474 ·Status: COMPLETED ·Phase: NA
-
Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)
NCT04774250 ·Status: TERMINATED ·Phase: PHASE2